160 related articles for article (PubMed ID: 33001278)
1. The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.
He L; Zhang T; Sun W; Qin Y; Wang Z; Dong W; Zhang H
Med Oncol; 2020 Oct; 37(11):97. PubMed ID: 33001278
[TBL] [Abstract][Full Text] [Related]
2. Saxagliptin protects against hypoxia-induced damage in H9c2 cells.
Zhang L; Qi X; Zhang G; Zhang Y; Tian J
Chem Biol Interact; 2020 Jan; 315():108864. PubMed ID: 31629700
[TBL] [Abstract][Full Text] [Related]
3. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.
Wang H; Liu X; Long M; Huang Y; Zhang L; Zhang R; Zheng Y; Liao X; Wang Y; Liao Q; Li W; Tang Z; Tong Q; Wang X; Fang F; Rojo de la Vega M; Ouyang Q; Zhang DD; Yu S; Zheng H
Sci Transl Med; 2016 Apr; 8(334):334ra51. PubMed ID: 27075625
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway.
Chen Z; Yu J; Fu M; Dong R; Yang Y; Luo J; Hu S; Li W; Xu X; Tu L
Biochem Pharmacol; 2020 Jul; 177():113951. PubMed ID: 32251672
[TBL] [Abstract][Full Text] [Related]
5. Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment.
Shen H; Yang Y; Xia S; Rao B; Zhang J; Wang J
Dis Esophagus; 2014; 27(7):685-92. PubMed ID: 24028437
[TBL] [Abstract][Full Text] [Related]
6. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB.
Ma S; Bai Z; Wu H; Wang W
Eur J Pharmacol; 2019 May; 851():186-193. PubMed ID: 30639312
[TBL] [Abstract][Full Text] [Related]
7. Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1α/CXCR4, and Kim-1/STAT3/HIF-1α/VEGF/eNOS pathways.
Kamel NM; Abd El Fattah MA; El-Abhar HS; Abdallah DM
Eur J Pharmacol; 2019 Oct; 861():172620. PubMed ID: 31437429
[TBL] [Abstract][Full Text] [Related]
8. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.
Choi SH; Park S; Oh CJ; Leem J; Park KG; Lee IK
Vascul Pharmacol; 2015 Oct; 73():11-9. PubMed ID: 26187356
[TBL] [Abstract][Full Text] [Related]
10. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
11. The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients.
Poncina N; Albiero M; Menegazzo L; Cappellari R; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2014 May; 13():92. PubMed ID: 24886621
[TBL] [Abstract][Full Text] [Related]
12. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
[TBL] [Abstract][Full Text] [Related]
13. Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats.
Ikeda J; Kimoto N; Kitayama T; Kunori S
J Pharmacol Sci; 2016 Sep; 132(1):65-70. PubMed ID: 27666017
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.
Dong J; Gong Y; Liu J; Chen X; Wen X; Sun H
Bioorg Med Chem; 2014 Feb; 22(4):1383-93. PubMed ID: 24457090
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction involved in lipoxin A4‑induced protection of tubular epithelial cells against hypoxia/reoxygenation injury.
Wu SH; Wang MJ; Lü J; Chen XQ
Mol Med Rep; 2017 Apr; 15(4):1682-1692. PubMed ID: 28259922
[TBL] [Abstract][Full Text] [Related]
16. Nrf2-heme oxygenase-1 axis in mucoepidermoid carcinoma of the lung: Antitumoral effects associated with down-regulation of matrix metalloproteinases.
Tertil M; Golda S; Skrzypek K; Florczyk U; Weglarczyk K; Kotlinowski J; Maleszewska M; Czauderna S; Pichon C; Kieda C; Jozkowicz A; Dulak J
Free Radic Biol Med; 2015 Dec; 89():147-57. PubMed ID: 26393425
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Boulton DW
Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-κB activity and Nrf2-dependent induction of HO-1 expression.
Jayasooriya RG; Park SR; Choi YH; Hyun JW; Chang WY; Kim GY
Environ Toxicol Pharmacol; 2015 May; 39(3):1189-98. PubMed ID: 25941985
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Lee JJ; Wang TY; Liu CL; Chien MN; Chen MJ; Hsu YC; Leung CH; Cheng SP
J Clin Endocrinol Metab; 2017 Aug; 102(8):2930-2940. PubMed ID: 28575350
[TBL] [Abstract][Full Text] [Related]
20. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases.
Sikorska J; Gaweł D; Domek H; Rudzińska M; Czarnocka B
BMC Cancer; 2019 Jan; 19(1):85. PubMed ID: 30654768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
